IL127170A0 - Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders - Google Patents

Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders

Info

Publication number
IL127170A0
IL127170A0 IL12717097A IL12717097A IL127170A0 IL 127170 A0 IL127170 A0 IL 127170A0 IL 12717097 A IL12717097 A IL 12717097A IL 12717097 A IL12717097 A IL 12717097A IL 127170 A0 IL127170 A0 IL 127170A0
Authority
IL
Israel
Prior art keywords
neurological disorders
tetrahydropteridines
pyridylpiperazines
treatment
crf
Prior art date
Application number
IL12717097A
Other languages
English (en)
Original Assignee
Du Pont Pharm Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Du Pont Pharm Co filed Critical Du Pont Pharm Co
Publication of IL127170A0 publication Critical patent/IL127170A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL12717097A 1996-05-23 1997-05-19 Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders IL127170A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1819896P 1996-05-23 1996-05-23
PCT/US1997/008448 WO1997044038A1 (en) 1996-05-23 1997-05-19 Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders

Publications (1)

Publication Number Publication Date
IL127170A0 true IL127170A0 (en) 1999-09-22

Family

ID=21786748

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12717097A IL127170A0 (en) 1996-05-23 1997-05-19 Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders

Country Status (14)

Country Link
US (3) US6083948A (da)
EP (1) EP0901374B1 (da)
JP (1) JP2000511183A (da)
AT (1) ATE255896T1 (da)
AU (1) AU739269B2 (da)
CA (1) CA2255650A1 (da)
DE (1) DE69726724T2 (da)
DK (1) DK0901374T3 (da)
ES (1) ES2213216T3 (da)
IL (1) IL127170A0 (da)
NZ (1) NZ332704A (da)
PT (1) PT901374E (da)
WO (1) WO1997044038A1 (da)
ZA (1) ZA973884B (da)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1129096E (pt) * 1998-11-12 2003-09-30 Neurocrine Biosciences Inc Antagonistas de receptor de crf e metodos de tratamento relacionados com os mesmos
ES2180338T3 (es) * 1998-11-12 2003-02-01 Neurocrine Biosciences Inc Antagonistas del receptor de crf y metodos relacionados.
US6531475B1 (en) * 1998-11-12 2003-03-11 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto
EP1040831A3 (en) * 1999-04-02 2003-05-02 Pfizer Products Inc. Use of corticotropin releasing factor (CRF) antagonists to prevent sudden death
US6432989B1 (en) 1999-08-27 2002-08-13 Pfizer Inc Use of CRF antagonists to treat circadian rhythm disorders
PL354784A1 (en) 1999-09-30 2004-02-23 Neurogen Corporation Certain alkylene diamine-substituted heterocycles
TWI271406B (en) 1999-12-13 2007-01-21 Eisai Co Ltd Tricyclic condensed heterocyclic compounds, preparation method of the same and pharmaceuticals comprising the same
US7235551B2 (en) * 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
EP1278751A1 (en) * 2000-05-01 2003-01-29 Bristol-Myers Squibb Pharma Company Tricyclic fused pyridine and pyrimidine derivatives as crf receptor antagonists
US6440960B1 (en) 2000-05-18 2002-08-27 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto
BR0111937A (pt) * 2000-07-19 2005-04-12 Bristol Myers Squibb Pharma Co Ligantes crf2 em terapia combinada
CN100525768C (zh) * 2000-10-23 2009-08-12 史密丝克莱恩比彻姆公司 新化合物
AU2002249474B2 (en) * 2001-04-30 2006-01-12 Glaxo Group Limited Crf receptor antagonists
US7446108B2 (en) * 2001-05-21 2008-11-04 Neurocrine, Inc. Tri-and tetraaza-acenaphthylen derivatives as CRF receptor antagonists
KR20040103972A (ko) * 2002-04-19 2004-12-09 스미스클라인 비참 코포레이션 신규 화합물
US7067658B2 (en) * 2002-09-30 2006-06-27 Bristol-Myers Squibb Company Pyridino and pyrimidino pyrazinones
US7572805B2 (en) 2004-07-14 2009-08-11 Bristol-Myers Squibb Company Pyrrolo(oxo)isoquinolines as 5HT ligands
EP1846410B1 (en) * 2005-02-10 2009-01-21 Bristol-Myers Squibb Company Dihydroquinazolinones as 5ht modulators
CA2614223A1 (en) * 2005-02-24 2006-08-31 Dr Pharma Nova, Llc A registry method and control system for dea schedule ii-v medicines
PE20061193A1 (es) * 2005-03-25 2006-12-02 Glaxo Group Ltd DERIVADOS DE 3,4-DIHIDROPIRIMIDO[4,5-d]PIRIMIDIN-2-[1H]-0NA COMO INHIBIDORES DE QUINASA p38
MY145343A (en) * 2005-03-25 2012-01-31 Glaxo Group Ltd Novel compounds
US7423042B2 (en) * 2005-03-25 2008-09-09 Glaxo Group Limited Compounds
US20080096905A1 (en) * 2005-03-25 2008-04-24 Glaxo Group Limited Process For Preparing Pyrido[2,3-D]Pyrimidin-7-One And 3,4-Dihydropyrimido{4,5-D}Pyrimidin-2(1H)-One Derivatives
KR20080034171A (ko) * 2005-07-28 2008-04-18 브리스톨-마이어스 스큅 컴퍼니 세로토닌 수용체 효능제 및 길항제로서의 치환된테트라히드로-1ｈ-피리도[4,3,ｂ]인돌
US7795436B2 (en) * 2005-08-24 2010-09-14 Bristol-Myers Squibb Company Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
AU2007238690B2 (en) 2006-04-12 2013-05-02 Vertex Pharmaceuticals Incorporated 4, 5-dihydro- [1, 2, 4] triazolo [4, 3-f] pteridines as protein kinase PLK1 inhibitors for the treatment of proliferative disorders
JP2009541284A (ja) * 2006-06-23 2009-11-26 アストラゼネカ・アクチエボラーグ プテリジン誘導体およびカテプシン阻害剤としてのそれらの使用
EP2266990B1 (en) 2008-04-15 2012-09-26 Eisai R&D Management Co., Ltd. 3-PHENYLPYRAZOLO[5,1-b]THIAZOLE COMPOUND
RS53347B (sr) 2008-12-09 2014-10-31 Gilead Sciences, Inc. Modulatori toll-sličnih receptora
US8551996B2 (en) * 2009-02-20 2013-10-08 Emory University Compounds, compositions, methods of synthesis, and methods of treatment
CA2772253C (en) 2009-09-14 2018-02-27 Gilead Sciences, Inc. Modulators of toll-like receptors
CN102548994A (zh) 2009-09-25 2012-07-04 沃泰克斯药物股份有限公司 用于制备用作蛋白激酶抑制剂的嘧啶衍生物的方法
CN103492391A (zh) 2009-09-25 2014-01-01 沃泰克斯药物股份有限公司 用于制备用作蛋白激酶抑制剂的嘧啶衍生物的方法
EP2580276A1 (en) 2010-06-10 2013-04-17 Union Carbide Chemicals & Plastics Technology LLC Thiobis phenolic antioxidant/polyethylene glycol blends
US8609672B2 (en) 2010-08-27 2013-12-17 University Of The Pacific Piperazinylpyrimidine analogues as protein kinase inhibitors
JP5848442B2 (ja) 2011-05-20 2016-01-27 ユニオン カーバイド ケミカルズ アンド プラスティックス テクノロジー エルエルシー チオビスフェノール系酸化防止剤／ポリエチレングリコールのブレンド
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
JP6522732B2 (ja) 2014-07-11 2019-05-29 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖを治療するためのトール様受容体の調節因子
CR20170077A (es) 2014-08-04 2017-06-26 Nuevolution As Derivados de heterociclilo opcionalmente condensados de pirimidina útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias
SG11201701520TA (en) 2014-09-16 2017-04-27 Gilead Sciences Inc Solid forms of a toll-like receptor modulator
KR102306860B1 (ko) 2014-09-16 2021-09-30 길리애드 사이언시즈, 인코포레이티드 톨-유사 수용체 조정제를 제조하는 방법
EP3325490B1 (en) 2015-07-23 2019-12-18 Takeda Pharmaceutical Company Limited 1-substituted 1,2,3,4-tetrahydro-1,7-naphthyridin-8-amine derivatives and their use as ep4 receptor antagonists
WO2017056115A1 (en) * 2015-10-03 2017-04-06 Sun Pharma Advanced Research Company Limited Novel n-aryl containing fused heterocyclic compounds
CN108473495B (zh) 2015-11-20 2022-04-12 福马治疗有限公司 作为泛素-特异性蛋白酶1抑制剂的嘌呤酮
TWI810456B (zh) 2019-05-22 2023-08-01 美商基利科學股份有限公司 Tlr7調節化合物及hiv疫苗之組合
MX2022007265A (es) 2019-12-20 2022-09-09 Nuevolution As Compuestos activos frente a receptores nucleares.
UY38994A (es) 2019-12-20 2021-07-30 Nuevolution As Compuestos activos frente a receptores nucleares
AU2021245397A1 (en) 2020-03-31 2022-10-20 Nuevolution A/S Compounds active towards nuclear receptors
WO2021198956A1 (en) 2020-03-31 2021-10-07 Nuevolution A/S Compounds active towards nuclear receptors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3127402A (en) * 1964-03-31 Y-oxopteridine derivatives
US4077955A (en) * 1977-02-17 1978-03-07 E. R. Squibb & Sons, Inc. Amino derivatives of 1,2,3,4-tetrahydro-2-oxopyrido[2,2-b]-pyrazine carboxylic acids and esters
EP0008864A1 (en) * 1978-08-15 1980-03-19 FISONS plc Pyridopyrazine and quinoxaline derivatives, processes for their preparation, and pharmaceutical compositions containing them
FI823156L (fi) * 1981-09-16 1983-03-17 Ciba Geigy Ag Foerfarande foer framstaellning av nya polycykliska polyazaheterocykler
US4510141A (en) * 1982-09-13 1985-04-09 Ciba-Geigy Corporation Tricyclic polyazaheterocycles for treating depression or anxiety
GB8318833D0 (en) * 1983-07-12 1983-08-10 Wellcome Found Chemical compounds
ZA836957B (en) * 1982-09-20 1985-04-24 Wellcome Found Neurologically active chemical compounds
HU221425B (en) 1990-11-06 2002-10-28 Yamanouchi Pharma Co Ltd Condensed pyrazine derivatives, process for their production and pharmaceutical preparations containing these compounds
US5198547A (en) * 1992-03-16 1993-03-30 South Alabama Medical Science Foundation, Usa Process for N5-formylating tetrahydropteridines
TW274550B (da) * 1992-09-26 1996-04-21 Hoechst Ag
FI964893A7 (fi) * 1994-06-06 1996-12-05 Pfizer Substituoituja pyratsoleja, jotka ovat aktiivisia kortikotropiinin vap auttamistekijän (CRF) antagonisteina
TW530047B (en) 1994-06-08 2003-05-01 Pfizer Corticotropin releasing factor antagonists
DK0765327T3 (da) 1994-06-16 1999-11-29 Pfizer Pyrazolo- og pyrrolopyridiner
JP3273108B2 (ja) * 1994-09-21 2002-04-08 アサヒビール株式会社 新規ピリド〔２，３−ｄ〕ピリミジン誘導体及びその製造方法

Also Published As

Publication number Publication date
PT901374E (pt) 2004-04-30
EP0901374A4 (en) 2001-05-09
DE69726724T2 (de) 2004-12-09
US6869955B2 (en) 2005-03-22
ATE255896T1 (de) 2003-12-15
EP0901374B1 (en) 2003-12-10
US20030064993A1 (en) 2003-04-03
JP2000511183A (ja) 2000-08-29
EP0901374A1 (en) 1999-03-17
AU3131697A (en) 1997-12-09
US6083948A (en) 2000-07-04
ZA973884B (en) 1998-11-06
AU739269B2 (en) 2001-10-11
WO1997044038A1 (en) 1997-11-27
US6399609B1 (en) 2002-06-04
ES2213216T3 (es) 2004-08-16
DE69726724D1 (de) 2004-01-22
DK0901374T3 (da) 2004-04-05
NZ332704A (en) 2000-05-26
CA2255650A1 (en) 1997-11-27

Similar Documents

Publication Publication Date Title
IL127170A0 (en) Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders
WO1997035539A3 (en) Arylamino fused pyridines and pyrimidines
PL342183A1 (en) Azolo-triazines and-pyrimidines
AU4270297A (en) Pyrazinones and triazinones and their derivatives thereof
GR3029561T3 (en) Pyrrolopyrimidines as crf antagonists.
YU90503A (sh) Supstituisani pirazinoni, piridini i pirimidini kao faktor oslobađanja kortikotropina
MY132871A (en) Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders
DE69807085D1 (de) Heterocyclyl-substituierte annellierte pyridine und pyrimidine als antagonisten des corticotropin freisetzenden hormons (crh), verwendbar für die behandlung von cns und stress
IL114061A0 (en) Methods of administering crf antagonists
NZ335052A (en) Piperazino derivatives as neurokinin antagonists
EP1380298A3 (en) Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders, anorexia, inflammation
MY141511A (en) Azolo triazines and pyrimidines
MY141752A (en) Pyrazolotriazines as crf antagonists
MY141976A (en) Azolo triazines and pyrimidines
JO1977B1 (en) Manufacture and use of Philippine tulips (flvx) in wastewater treatment